Navigation Links
Occlutech Obtains Favourable Court Ruling in Patent Litigation in The Hague Against AGA Medical
Date:10/30/2008

JENA, Germany, October 30 /PRNewswire/ -- Occlutech GmbH, the leading European manufacturer of cardiac occlusion devices, today announced that it has won its litigation case in The Hague, Holland, against AGA Medical Inc. regarding non-infringement of the Dutch version of the European patent; EP 0808138.

The patent court in The Hague stated that the disputed Occlutech products do not infringe the Dutch part of; EP 0808138 (equivalent of German patent DE 695 34 505.2) held by AGA Medical. In reaching its decision, the Dutch court had full access to the now appealed 2007 German District Court's ruling resulting from litigation initiated by AGA Medical in 2006.

Patent infringement litigation against a previous version of the occluder was originally filed in Germany by AGA Medical Inc. In Occlutech's view, AGA Medical argued for an extraordinarily broad interpretation of its granted patent claims, contributing to Occlutech's defeat in the first instance district court's ruling. The broad scope of the claim, interpreted before the German court in 2007, was however not accepted by the European Patent Office's examiners during the original patent granting procedure. This and several other factors created significant and in Occlutech's view justified reasons for appealing the district court ruling in Germany and for Occlutech to initiate non-infringement proceedings internationally and, in particular, before the patent court in The Hague, Holland. The Dutch patent court's ruling will become final if no appeal is filed.

In a statement, Tor Peters, Chairman of Occlutech AB, says: "We are very pleased with the decision of the patent court in The Hague, which had access to all relevant information available, including information submitted at the appeal proceedings in Germany. This shows that Occlutech's patented technology is substantially different from AGA's and we look forward to continue our surge, establishing a global presence."

Occlusion devices are used to treat structural heart disease, including structural heart defects and abnormalities such as Atrial Septal Defects, (ASD), and Patent Foramen Ovale (PFO, an undesired channel between the heart's two atria, present in up to 25% of the population), in minimally invasive, non-surgical procedures. The market for PFO occluders is expected to expand significantly as the link between PFO and stroke, that is the third most common cause of death, as well as severe migraine becomes increasingly well documented.

Contacts:

Tor Peters

tor.peters@occlutech.se

+46-42-33-65-20

Susanne Goransson

susanne.goransson@occlutech.net

+46-42-33-65-21


'/>"/>
SOURCE Occlutech GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
2. Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With Regard to Patents Held by AGA Medical
3. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
4. Botaneco obtains $2.4 million in funding from AVAC
5. Ganeden Biotech Obtains Self-Affirmed GRAS Status for Probiotic Ingredient, GanedenBC30 (Bacillus coagulans GBI-30, 6086)
6. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
7. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
8. China Kangtai Cactus Biotech, Inc. Obtains $500,000 Equity Financing
9. PerOs obtains USDA Establishment and Product Licenses for its oral vaccine formulations
10. Biofisica Obtains $2.3 Million in Financing From Investors
11. First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... They call it the “hairy ... a depiction of a system of linkages and connections so complex and dense ... of computer science at Worcester Polytechnic Institute (WPI) and director of the university’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a United States multicenter, prospective clinical study that demonstrates the accuracy ... test capable of identifying clinically significant acute bacterial and viral respiratory tract ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... analysis platform specifically designed for life science researchers to analyze and interpret ... Rosalind Franklin, who made a major contribution to the discovery of the ...
(Date:10/11/2017)... ... , ... Personal eye wash is a basic first aid supply for any work environment, but ... do you rinse first if a dangerous substance enters both eyes? It’s one less decision, ... its unique dual eye piece. , “Whether its dirt and debris, or an acid or ...
Breaking Biology Technology:
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
Breaking Biology News(10 mins):